Adaptimmune Therapeutics PLC: Nasdaq/NYSE listing notice — Adaptimmune granted Nasdaq extension to Dec 1, 2025 to regain $1 bid compliance

Adaptimmune Therapeutics PLC

Nasdaq Hearings Panel granted exception until December 1, 2025 to meet minimum $1.00 bid price per share.
Notice received on September 22, 2025; failure to comply by deadline will lead to delisting of ADSs.
If non-compliant by December 1, 2025, trading will be suspended and delisting proceedings will commence.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Adaptimmune Therapeutics PLC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 22, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 will result in the delisting of the Company’s American Depositary Shares from The Nasdaq Capital Market. Forward-Looking Stat

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-25-093882

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.